Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.58 |
| ▸ | BTK | Q06187 | 5/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.53 |
| ▸ | AR | P10275 | 3/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29822185 | 1.00 | CRBN (0.58) | CRBNBTKDDB1AREGFR | |
| SCHEMBL29821987 | 0.92 | CRBN (0.56) | CRBNBTKDDB1AREGFR | |
| SCHEMBL25691418 | 0.92 | CRBN (0.47) | CRBNBTKDDB1AREGFR | |
| SCHEMBL23117846 | 0.92 | CRBN (0.56) | CRBNBTKDDB1AREGFR | |
| SCHEMBL23133938 | 0.92 | CRBN (0.69) | CRBNBTKDDB1HPGDS | |
| SCHEMBL23117874 | 0.90 | CRBN (0.60) | CRBNBTKDDB1AREGFR | |
| SCHEMBL29822046 | 0.90 | CRBN (0.60) | CRBNBTKDDB1AREGFR | |
| SCHEMBL24299348 | 0.90 | CRBN (0.66) | CRBNBTKDDB1AREGFR | |
| SCHEMBL29986989 | 0.90 | CRBN (0.66) | CRBNBTKDDB1AREGFR | |
| SCHEMBL29597621 | 0.89 | BTK (0.56) | CRBNBTKDDB1AREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761003-B | Novel ureas having androgen receptor degrading activity and uses thereof | 冰洲石生物科技公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-11420956-B2 | Ureas having Androgen Receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-114761003-A | Novel ureas having androgen receptor degrading activity and use thereof | 冰洲石生物科技公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2022048605-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATIONS | 南昌奥瑞药业有限公司 | 2022-03-10 | — | — | WO | disclosed |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021061642-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021061642-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20210087170-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210087170-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420956-B2 | Ureas having Androgen Receptor degradation activity and uses thereof | AR, UTS2R, ESRRA | CRBN 1098/4885BTK 3911/4885DDB1 1270/4885 |
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885BTK 3930/4885DDB1 1112/4885 |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | AR, UTS2R, ESRRA | CRBN 1098/4885BTK 3911/4885DDB1 1270/4885 |
| US-20210087170-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885BTK 3930/4885DDB1 1112/4885 |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885BTK 3930/4885DDB1 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.